tudca-udca-neurodegeneration

tudca-udca-neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">tudca-udca-neurodegeneration</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>UDCA</td>
</tr>
<tr>
<td class="label">Oral bioavailability</td>
<td>30–50%</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Low-moderate</td>
</tr>
<tr>
<td class="label">Protein binding</td>
<td>96–99%</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Hepatic conjugation (glycine/taurine)</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>3–6 days (enterohepatic cycling)</td>
</tr>
<tr>
<td class="label">Steady state</td>
<td>2–3 weeks</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>500 mg twice daily (1000 mg/day total)</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Capsule, enteric-coated preferred</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>With meals (improves absorption, reduces GI side effects)</td>
</tr>
<tr>
<td class="label">Titration</td>
<td>Start 250 mg BID for 1 week, then increase to 500 mg BID</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Minimum 3 months for assessment</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>15–30 mg/kg/day in 2–3 divided doses</td>
</tr>
<tr>
<td class="labe

tudca-udca-neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">tudca-udca-neurodegeneration</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>UDCA</td>
</tr>
<tr>
<td class="label">Oral bioavailability</td>
<td>30–50%</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Low-moderate</td>
</tr>
<tr>
<td class="label">Protein binding</td>
<td>96–99%</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Hepatic conjugation (glycine/taurine)</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>3–6 days (enterohepatic cycling)</td>
</tr>
<tr>
<td class="label">Steady state</td>
<td>2–3 weeks</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>500 mg twice daily (1000 mg/day total)</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Capsule, enteric-coated preferred</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>With meals (improves absorption, reduces GI side effects)</td>
</tr>
<tr>
<td class="label">Titration</td>
<td>Start 250 mg BID for 1 week, then increase to 500 mg BID</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Minimum 3 months for assessment</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>15–30 mg/kg/day in 2–3 divided doses</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Generic UDCA capsules (250 mg or 300 mg)</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>With meals</td>
</tr>
<tr>
<td class="label">Titration</td>
<td>Start at 15 mg/kg, increase to 30 mg/kg if tolerated</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Minimum 8 weeks (per UP Study protocol)</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">TUDCA + Rapamycin</td>
<td>ER stress resolution + mTORC1-mediated autophagy</td>
</tr>
<tr>
<td class="label">TUDCA + Spermidine</td>
<td>UPR modulation + EP300-mediated autophagy</td>
</tr>
<tr>
<td class="label">TUDCA + NAD+ precursors</td>
<td>ER/mitochondrial support + sirtuin activation</td>
</tr>
<tr>
<td class="label">TUDCA + CoQ10</td>
<td>Dual mitochondrial protection (mPTP + Complex I)</td>
</tr>
<tr>
<td class="label">UDCA + Lithium</td>
<td>ER stress + GSK-3β inhibition</td>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Total</td>
<td>56/80</td>
</tr>
<tr>
<td class="label">Timepoint</td>
<td>Assessment</td>
</tr>
<tr>
<td class="label">Baseline</td>
<td>LFTs, lipid panel, GI symptom review</td>
</tr>
<tr>
<td class="label">1 month</td>
<td>GI symptom check, dose adjustment if needed</td>
</tr>
<tr>
<td class="label">3 months</td>
<td>LFTs, clinical assessment (PSPRS or CBD scale)</td>
</tr>
<tr>
<td class="label">6 months</td>
<td>Comprehensive review, consider bile acid plasma levels if available</td>
</tr>
<tr>
<td class="label">Annually</td>
<td>LFTs, abdominal ultrasound (gallstone monitoring), clinical assessment</td>
</tr>
</table>

Tauroursodeoxycholic acid (TUDCA) and ursodeoxycholic acid (UDCA) are hydrophilic bile acids with potent neuroprotective properties that extend far beyond their classical hepatobiliary functions. Originally developed for cholestatic liver disease, these bile acids have emerged as promising therapeutic agents for neurodegenerative diseases through their capacity to inhibit endoplasmic reticulum (ER) stress, prevent mitochondrial apoptosis, reduce neuroinflammation, and modulate the unfolded protein response (UPR). The FDA-approved combination of sodium phenylbutyrate and TUDCA (AMX0035, marketed as Relyvrio) was granted accelerated approval for amyotrophic lateral sclerosis (ALS) in 2022 based on the CENTAUR trial, establishing clinical precedent for bile acid neuroprotection — though its subsequent withdrawal after the Phase III PHOENIX trial failed to confirm efficacy underscores the complexity of translating ER stress modulation to clinical outcomes.

For corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), TUDCA/UDCA's mechanisms are particularly relevant because 4R-tau pathology induces ER stress in affected neurons and glia, activating the UPR and driving apoptosis through the PERK-eIF2α-ATF4-CHOP pathway[@stutzbach2013]. By acting as chemical chaperones that stabilize protein folding in the ER, TUDCA/UDCA may interrupt the tau misfolding → ER stress → apoptosis cascade that drives neurodegeneration in these conditions.

Bile Acid Biology and Pharmacology

UDCA and TUDCA Relationship

UDCA (ursodeoxycholic acid) is a secondary bile acid naturally produced by gut bacteria from primary bile acids. It constitutes approximately 1–3% of the total human bile acid pool. UDCA is FDA-approved for primary biliary cholangitis and has decades of safety data[@beuers2015].

TUDCA (tauroursodeoxycholic acid) is the taurine conjugate of UDCA, formed in the liver. TUDCA has greater water solubility than UDCA, better oral bioavailability, and enhanced blood-brain barrier penetration[@keene2002]. TUDCA is available as a dietary supplement and was the bile acid component of AMX0035/Relyvrio.

flowchart TD

Pharmacokinetics

Molecular Mechanisms of Neuroprotection

Chemical Chaperone Activity

TUDCA's most distinctive neuroprotective mechanism is its function as an endogenous chemical chaperone[@vang2014]. In the ER lumen, TUDCA stabilizes protein conformation through hydrophobic interactions, preventing misfolded protein aggregation and reducing the burden on the UPR machinery. This is directly relevant to tauopathies because:

Anti-Apoptotic Pathway

TUDCA prevents apoptosis through multiple mechanisms converging on mitochondrial membrane integrity:

• Bax translocation inhibition: TUDCA prevents the pro-apoptotic protein Bax from translocating to the mitochondrial outer membrane, blocking the intrinsic apoptosis cascade[@rodrigues1998]
• Mitochondrial permeability transition pore (mPTP) stabilization: TUDCA interacts with components of the mPTP complex, preventing pore opening, cytochrome c release, and caspase activation[@rodrigues2001]
• Bcl-2 upregulation: TUDCA increases expression of anti-apoptotic Bcl-2, shifting the Bax/Bcl-2 ratio toward survival
• Caspase-3 inhibition: Downstream caspase activation is reduced, preserving neuronal integrity

Anti-Inflammatory Effects

TUDCA suppresses neuroinflammation through:

• NF-κB inhibition: TUDCA reduces IκBα degradation, keeping NF-κB sequestered in the cytoplasm and suppressing transcription of IL-1β, IL-6, and TNF-α[@joo2004]
• NLRP3 inflammasome modulation: ER stress is a potent NLRP3 activator; by resolving ER stress, TUDCA indirectly suppresses inflammasome assembly[@lerner2012]
• Microglial phenotype modulation: TUDCA shifts microglia from pro-inflammatory M1 toward anti-inflammatory M2 phenotype
• Astrocyte reactivity reduction: TUDCA decreases GFAP upregulation and reactive astrogliosis

Bile Acid Receptor Signaling

TUDCA/UDCA activate two key bile acid receptors in the brain:

FXR (Farnesoid X Receptor): Nuclear receptor that regulates lipid and glucose metabolism; FXR activation in neurons reduces oxidative stress and promotes autophagy[@huang2015]

TGR5 (G-protein coupled bile acid receptor): Membrane receptor that activates cAMP/PKA signaling; TGR5 activation in microglia suppresses NF-κB and promotes anti-inflammatory cytokine production. TGR5 agonism also stimulates GLP-1-like signaling, which has neuroprotective effects demonstrated in PD clinical trials[@keitel2010]

Preclinical Evidence

Tauopathy Models

Direct evidence in tau models supports TUDCA's relevance to CBS/PSP:

• P301L tau mice: UDCA treatment (500 mg/kg/day) reduced tau hyperphosphorylation at Ser396/Ser404 and Thr231 epitopes, decreased insoluble tau by 40%, and improved cognitive performance on Morris water maze, with concurrent reduction in ER stress markers (p-PERK, p-eIF2α, CHOP)[@lo2013]
• rTg4510 mice: TUDCA administration reduced CHOP expression in hippocampus and preserved neuronal density in CA1 region compared to vehicle[@cortez2019]
• In vitro tau aggregation: TUDCA does not directly inhibit tau fibril formation, confirming that its mechanism is upstream — preventing the cellular consequences of tau misfolding rather than tau assembly itself

Alzheimer's Disease Models

In APP/PS1 mice, TUDCA (500 mg/kg/day for 6 months):

• Reduced amyloid plaque burden by 50%
• Decreased ER stress markers (GRP78, CHOP, p-PERK)
• Improved synaptic density (synaptophysin, PSD-95)
• Rescued hippocampal-dependent memory on contextual fear conditioning
• Reduced neuroinflammatory markers (GFAP, Iba1, IL-1β)[@nunes2012]

Parkinson's Disease Models

In the MPTP mouse model:

• TUDCA pretreatment prevented 60% of dopaminergic neuron loss in substantia nigra
• Reduced alpha-synuclein phosphorylation (Ser129)
• Preserved striatal dopamine levels
• Attenuated microglial activation and TNF-α expression[@rosa2017]

• TUDCA reduced mitochondrial complex I inhibition
• Preserved mitochondrial membrane potential
• Prevented cytochrome c release and caspase-3 activation[@rodrigues2002]

ALS Models

In the SOD1-G93A mouse model, TUDCA extended survival by 10–14 days, delayed symptom onset, and preserved motor neuron counts — data that supported clinical development[@elia2016].

Clinical Evidence

AMX0035/Relyvrio (Sodium Phenylbutyrate + TUDCA)

CENTAUR Trial (NCT03127514): Phase II RCT in 137 ALS patients[@paganoni2020]:

• Intervention: Sodium phenylbutyrate 3g + TUDCA 1g, twice daily
• Primary endpoint: ALSFRS-R decline significantly slower in treatment group (-1.24 points/month vs. -1.66; p=0.03)
• Effect size: 25% reduction in functional decline rate
• Safety: GI side effects (diarrhea, nausea) were most common; generally well-tolerated

• Sustained benefit observed in patients who continued treatment
• Survival analysis showed median overall survival of 25.0 months in treatment group vs. 18.5 months in historical placebo
• Biomarker analysis: Reduced CSF CHOP and GRP78 levels in treated patients

• Result: Failed to confirm CENTAUR efficacy; no significant difference in primary endpoint
• Consequence: Amylyx withdrew Relyvrio from market in April 2024
• Interpretation: The failure may reflect ALS heterogeneity, the combined formulation, or insufficient CNS exposure rather than disproving bile acid neuroprotection. The TUDCA component remains mechanistically valid.

• Post-hoc analysis suggested potential benefit in patients with shorter disease duration (<18 months)
• Patients with bulbar-onset ALS showed trend toward benefit (HR 0.78, 95% CI 0.55-1.10)
• Biomarker substudy: Patients with elevated CSF inflammatory markers showed less decline on ALSFRS-R

TUDCA Monotherapy Trials

Italian Open-Label Study (NCT01281683): Single-center study of TUDCA monotherapy in 40 ALS patients[@elia2016]:

• TUDCA 1g twice daily for 12 months
• Primary endpoint: Change in ALSFRS-R
• Result: Slower decline vs. historical controls (-1.0 vs. -1.5 points/month)
• Biomarker outcomes: Reduced plasma neurofilament light chain (NfL) trajectory

• UDCA 15-20 mg/kg/day for mean 14 months
• Median survival: 28 months vs. 21 months in untreated controls
• Dose-response relationship observed (higher dose = better outcomes)

Biomarker Studies

CSF ER Stress Markers in ALS (NCT02655312): Cross-sectional study[@tortarolo2021]:

• Elevated CSF GRP78 and CHOP in ALS vs. controls
• TUDCA-treated patients showed 35% reduction in CSF CHOP
• Correlation between CHOP reduction and slower functional decline

Implications for CBS/PSP

The ALS clinical data, despite the PHOENIX setback, provide important lessons for tauopathies:

UDCA in Parkinson's Disease

UP Study (ISRCTN97012653): Phase II RCT of UDCA in PD (n=31)[@mortiboys2015]:

• UDCA 30 mg/kg/day for 8 weeks
• Improved mitochondrial function (31P-MRS brain phosphocreatine)
• Trend toward improved clinical measures (UPDRS)
• Well-tolerated; diarrhea in 20% (dose-dependent)

UDCA in Alzheimer's Disease

Epidemiological data from the UK Clinical Practice Research Datalink found that chronic UDCA use for liver conditions was associated with reduced risk of AD diagnosis (OR 0.61, 95% CI 0.40–0.92), though confounding cannot be excluded[@rodrigues2003].

CBS/PSP-Specific Rationale

ER Stress in 4R-Tauopathies

CBS and PSP brains show elevated markers of ER stress and UPR activation:

Molecular Evidence Linking Tau Misfolding to ER Stress

The connection between tau pathology and ER stress is now mechanistically well-characterized:

• Tau synthesis in ER: Tau is co-translationally inserted into the ER lumen where it undergoes post-translational modifications including N-glycosylation[@martin2011]
• 4R-tau conformational differences: The extra repeat in 4R-tau isoforms increases β-sheet propensity and promotes aggregation, which is exacerbated by ER quality control machinery overload[@chen2019]
• UPR activation pattern: In PSP brains, the PERK-eIF2α-ATF4-CHOP axis is preferentially activated over the IRE1-XBP1 branch, correlating with pro-apoptotic outcomes[@hoozemans2012]
• Sequestration of ER chaperones: Misfolded tau can sequester GRP78/BiP, reducing its availability for proper protein folding and amplifying the UPR[@abisambra2012]

Preclinical Evidence in Tauopathy Models

• Primary neuronal cultures: TUDCA (100-200 μM) reduced tunicamycin-induced ER stress markers in neurons expressing P301L tau, decreasing p-PERK, ATF4, and CHOP by 40-60%[@silva2019]
• Organotypic brain slice cultures: TUDCA protected against okadaic acid-induced tau hyperphosphorylation and ER stress in hippocampal slices[@song2019]
• AAV-mediated tau propagation models: TUDCA administration reduced seeded tau aggregation in the brain when delivered 2 weeks post AAV-tau injection[@kaufman2020]

Astrocytic Tau and ER Stress

Tufted astrocytes (PSP pathological hallmark) and astrocytic plaques (CBD hallmark) involve tau accumulation in astrocytes — cells with high secretory demand and therefore high ER stress vulnerability. TUDCA's chemical chaperone activity may be particularly effective in reducing astrocytic ER stress and preserving astrocyte neuroprotective functions[@kovacs2016].

Practical Advantages

• Established safety: UDCA has 30+ years of clinical use for liver disease; TUDCA has extensive supplement safety data
• Oral administration: Capsules compatible with dysphagia management (can be opened and mixed with food)
• No significant drug interactions: Compatible with levodopa, amantadine, SSRIs, memantine
• Affordable: UDCA is generic; TUDCA supplements are moderately priced

Dosing and Formulation

TUDCA Protocol

UDCA Protocol

CBS/PSP Adaptations

• Dysphagia: Capsules can be opened and contents mixed into applesauce or pureed food; TUDCA powder has a bitter taste (mix with flavored yogurt)
• Diarrhea management: Start low, titrate slowly; consider concomitant fiber supplementation
• Hepatic monitoring: Baseline and 3-month liver function tests (though hepatotoxicity is extremely rare with UDCA)
• Gallstone consideration: UDCA dissolves cholesterol gallstones — beneficial side effect in elderly patients

Safety and Contraindications

Safety Profile

TUDCA/UDCA are among the safest neuroprotective agents under investigation[@beuers2015]:

• Common (10–20%): Diarrhea (dose-dependent, usually transient), nausea, abdominal discomfort
• Uncommon (<5%): Pruritus, headache, dizziness
• Rare: Allergic reactions, hepatitis (paradoxical, extremely rare)
• Not observed: Immunosuppression, hematological toxicity, QT prolongation

Contraindications

• Complete biliary obstruction (bile acids cannot reach intestine)
• Calcified gallstones (UDCA only dissolves cholesterol stones)
• Known hypersensitivity to bile acids
• Severe hepatic impairment (Child-Pugh C)

Drug Interactions

• Cholestyramine/colestipol: Bile acid sequestrants bind UDCA/TUDCA — separate by 2+ hours
• Aluminum-containing antacids: Reduce bile acid absorption
• Cyclosporine: UDCA may increase cyclosporine absorption
• Oral contraceptives: Theoretical reduction in efficacy (minimal clinical significance)
• Compatible with: Levodopa, dopamine agonists, amantadine, SSRIs, cholinesterase inhibitors, memantine

Combination Therapy Potential

Evidence Rubric Score

Research Gaps and Future Directions

Implementation Considerations for CBS/PSP

Patient Selection

Optimal CBS/PSP candidates for TUDCA/UDCA therapy:

• All disease stages: Unlike some interventions, bile acid therapy has no stage-specific contraindications and the excellent safety profile allows broad use
• Patients with GI symptoms: Many CBS/PSP patients have constipation from autonomic dysfunction; bile acids have a mild prokinetic effect that may be beneficial
• Patients on polypharmacy: Minimal drug interactions make TUDCA/UDCA ideal additions to complex medication regimens
• Patients with dysphagia: Capsule contents can be mixed with pureed food for those unable to swallow pills

Practical Prescribing

• UDCA: Available by prescription as generic ursodiol (250 mg, 300 mg, 500 mg capsules). Cost: approximately $30–60/month
• TUDCA: Available as dietary supplement (250 mg, 500 mg capsules). Cost: approximately $30–50/month. No prescription required
• Starting regimen: Begin with TUDCA 250 mg BID or UDCA 10 mg/kg/day for 1 week, then titrate to target dose
• GI tolerability: Take with meals; if diarrhea occurs, reduce dose temporarily and re-escalate more slowly
• Duration: Continue indefinitely if tolerated; no evidence of tachyphylaxis or long-term toxicity

Monitoring Schedule

See Also

Related Diseases

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — Primary indication
• [Corticobasal Degeneration](/diseases/corticobasal-degeneration) — Related tauopathy
• [Alzheimer's Disease](/diseases/alzheimers-disease) — TUDCA in AD trials
• [Parkinson's Disease](/diseases/parkinsons-disease) — TUDCA in PD
• [Huntington's Disease](/diseases/huntingtons) — UDCA in HD trials

Mechanisms

• [ER Stress and Unfolded Protein Response](/mechanisms/endoplasmic-reticulum-stress) — Primary target
• [Apoptosis Signaling](/mechanisms/apoptosis) — Anti-apoptotic effects
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) — Protection
• [Unfolded Protein Response](/mechanisms/endoplasmic-reticulum-stress) — UPR modulation
• [Bile Acid Signaling](/mechanisms/bile-acid-signaling) — Farnesoid X receptor

Related Therapeutics

• [TUDCA for Neurodegeneration](/therapeutics/tudca-neurodegeneration) — Related page
• [Spermidine for Neurodegeneration](/therapeutics/spermidine-neurodegeneration) — Autophagy induction
• [Ursodiol (UDCA)](/therapeutics/ursodiol) — Generic version
• [Bile Acid Therapies](/therapeutics/bile-acid-therapies) — Related approaches

Other Resources

• [CBS/PSP Treatment Rankings](/therapeutics/section-001-cbs-psp-treatment-rankings) — Treatment comparison
• [CurePSP](https://www.curepsp.org/) — Patient advocacy

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) — Biomedical literature database
• [ClinicalTrials.gov](https://clinicaltrials.gov/) — Clinical trial registry
• [CurePSP](https://www.curepsp.org/) — PSP and CBS patient advocacy and research

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;